Bruker Co. (NASDAQ:BRKR) Stock Position Decreased by Comerica Bank

Comerica Bank lessened its holdings in shares of Bruker Co. (NASDAQ:BRKR – Get Rating) by 1.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 45,813 shares of the medical research company’s stock after selling 690 shares during the period. Comerica Bank’s holdings in Bruker were worth $2,687,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Bruker by 4.5% during the 1st quarter. Vanguard Group Inc. now owns 11,253,314 shares of the medical research company’s stock valued at $723,588,000 after buying an additional 487,688 shares during the last quarter. BlackRock Inc. grew its position in Bruker by 2.7% in the 1st quarter. BlackRock Inc. now owns 11,135,940 shares of the medical research company’s stock worth $716,042,000 after purchasing an additional 291,386 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Bruker by 36.2% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,188,371 shares of the medical research company’s stock worth $388,380,000 after purchasing an additional 1,643,289 shares during the last quarter. State Street Corp grew its position in Bruker by 2.2% in the 2nd quarter. State Street Corp now owns 3,078,511 shares of the medical research company’s stock worth $193,207,000 after purchasing an additional 67,217 shares during the last quarter. Finally, Brown Advisory Inc. grew its position in Bruker by 24.2% in the 2nd quarter. Brown Advisory Inc. now owns 1,393,957 shares of the medical research company’s stock worth $87,485,000 after purchasing an additional 272,010 shares during the last quarter. Institutional investors own 70.40% of the company’s stock.

Bruker Trading Down 0.7 %

Shares of NASDAQ:BRKR opened at $68.05 on Wednesday. The company has a 50 day moving average of $67.28 and a 200-day moving average of $62.25. The firm has a market cap of $10.01 billion, a P/E ratio of 37.19, a P/E/G ratio of 2.32 and a beta of 1.18. Bruker Co. has a twelve month low of $48.42 and a twelve month high of $74.94. The company has a current ratio of 2.36, a quick ratio of 1.49 and a debt-to-equity ratio of 1.20.

Bruker (NASDAQ:BRKR – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.53 by $0.13. The company had revenue of $638.90 million during the quarter, compared to analyst estimates of $613.53 million. Bruker had a net margin of 10.97% and a return on equity of 32.58%. As a group, analysts anticipate that Bruker Co. will post 2.31 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, December 16th. Investors of record on Thursday, December 1st were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend was Wednesday, November 30th. Bruker’s dividend payout ratio is presently 10.93%.

Analyst Ratings Changes

BRKR has been the subject of several recent analyst reports. StockNews.com upgraded shares of Bruker from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 7th. UBS Group initiated coverage on shares of Bruker in a research report on Friday, October 21st. They issued a “buy” rating and a $70.00 target price for the company. Cowen decreased their target price on shares of Bruker to $75.00 in a research report on Wednesday, November 16th. Finally, TheStreet upgraded shares of Bruker from a “c+” rating to a “b-” rating in a research report on Friday, November 4th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $74.00.

Insider Activity at Bruker

In related news, Director Richard A. Packer sold 20,000 shares of the stock in a transaction that occurred on Tuesday, December 6th. The shares were sold at an average price of $66.18, for a total transaction of $1,323,600.00. Following the completion of the sale, the director now directly owns 59,907 shares of the company’s stock, valued at $3,964,645.26. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 27.60% of the company’s stock.

Bruker Profile

(Get Rating)

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies.